Opsona Therapeutics appoints chief medical officer

Chief executive steps down for personal reasons

Opsona Therapeutics, based in Dublin, Ireland, has appointed Leon Hooftman as chief medical officer. Dr Hooftman was formerly CMO at Chroma Therapeutics (UK). Prior to this he was head of clinical development at Celltech (UK). Hooftman has also worked for Hoffmann La-Roche and Syntex.

Chief executive Dr Mark Heffernan has stepped down for personal reasons but will remain as a non-executive board member. Bernd Seizinger has been appointed executive chairman and will oversee the search for a new ceo and assume additional responsibilities for the company's operations during this period.

To further strengthen the executive management team, one of the company's founding scientists and directors, Professor Luke O'Neill will assume the additional role of chief scientific officer.

Opsona's vp of pharmaceutical development, Mary Reilly, has taken a broader role within the company as vice president of pharmaceutical development and operations.

You may also like

Research & Development

Opsona Therapeutics wins EC research grant of €5.9m

For the clinical development of lead drug candidate OPN-305
Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Manufacturing

Aenova expands Killorglin site with spray drying platform

New equipment to help overcome bioavailability hurdles and accelerate time-to-market
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Subscribe now